Flavonoids, phenoxodiol, and a novel agent, triphendiol, for the treatment of pancreaticobiliary cancers

Bibliography

• American Cancer Society: cancer facts and figures 2008. Atlanta, GA: American Cancer Society; 2008
   Google Scholar
• Saif MW. Pancreatic cancer: is this bleak landscape finally changing? JOP2007;8(4):365-73
   PubMedGoogle Scholar
• Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol1997;15:2403-13
   PubMed Web of Science ®Google Scholar
• Saif MW. Is there a standard of care for the management of advanced pancreatic cancer? JOP2008;9(2):91-8
   PubMedGoogle Scholar
• Kale A, Gawande S, Kotwal S. Cancer phytotherapeutics: role for flavonoids at the cellular level. Phytother Res2008;22(5):567-77
   PubMed Web of Science ®Google Scholar
• Lopez-Lazaro M. Flavonoids as anticancer agents: structure-activity relationship study. Curr Med Chem AntiCancer Agents2002;2(6):691-714
   PubMedGoogle Scholar
• Wang HK. The therapeutic potential of flavonoids. Expert Opin Invest Drugs2000;9:2103-19
   PubMed Web of Science ®Google Scholar
• Neukam K, Pastor N, Cortés F. Tea flavanols inhibit cell growth and DNA topoisomerase II activity and induce endoreduplication in cultured Chinese hamster cells. Mutat Res2008;654(1):8-12
   PubMed Web of Science ®Google Scholar
• Shankar S, Ganapathy S, Hingorani SR, Srivastava RK. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci2008;13:440-52
   PubMed Web of Science ®Google Scholar
• Shankar S, Suthakar G, Srivastava RK. Epigallocatechin-3-gallate inhibits cell cycle and induces apoptosis in pancreatic cancer. Front Biosci2007;12:5039-51
   PubMed Web of Science ®Google Scholar
• Tan M, Norwood A, May M, et al. Effects of (-)epigallocatechin gallate and thymoquinone on proliferation of a PANC-1 cell line in culture. Biomed Sci Instrum2006;42:363-71
   PubMedGoogle Scholar
• Qanungo S, Das M, Haldar S, Basu A. Epigallocatechin-3-gallate induces mitochondrial membrane depolarization and caspase-dependent apoptosis in pancreatic cancer cells. Carcinogenesis2005;26(5):958-67
   PubMed Web of Science ®Google Scholar
• Takada M, Nakamura Y, Koizumi T, et al. Suppression of human pancreatic carcinoma cell growth and invasion by epigallocatechin-3-gallate. Pancreas2002;25(1):45-8
   PubMed Web of Science ®Google Scholar
• Artali R, Beretta G, Morazzoni P, et al. Green tea catechins in chemoprevention of cancer: a molecular docking investigation into their interaction with glutathione S-transferase (GST P1-1). J Enzyme Inhib Med Chem2009;24(1):287-95
   PubMed Web of Science ®Google Scholar
• Qin J, Chen HG, Yan Q, et al. Protein phosphatase-2A is a target of epigallocatechin-3-gallate and modulates p53-Bak apoptotic pathway. Cancer Res2008;68(11):4150-62
   PubMed Web of Science ®Google Scholar
• Na HK, Kim EH, Jung JH, et al. (-)-Epigallocatechin gallate induces Nrf2-mediated antioxidant enzyme expression via activation of PI3K and ERK in human mammary epithelial cells. Arch Biochem Biophys2008;476(2):171-7
   PubMed Web of Science ®Google Scholar
• Newcomb EW. Flavopiridol: pleiotropic biological effects enhance its anti-cancer activity. Anticancer Drugs2004;15(5):411-9
   PubMed Web of Science ®Google Scholar
• Shapiro GI. Preclinical and clinical development of the cyclin-dependent kinase inhibitor flavopiridol. Clin Cancer Res2004;10(12 Pt 2):4270s-5s
   PubMed Web of Science ®Google Scholar
• Schwartz GK, O'Reilly E, Ilson D, et al. Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. J Clin Oncol2002;20(8):2157-70
   PubMed Web of Science ®Google Scholar
• Banerjee S, Zhang Y, Ali S, et al. Molecular evidence for increased antitumor activity of gemcitabine by genistein in vitro and in vivo using an orthotopic model of pancreatic cancer. Cancer Res2005;65(19):9064-72
   PubMed Web of Science ®Google Scholar
• Banerjee S, Li Y, Wang Z, Sarkar FH. Multi-targeted therapy of cancer by genistein. Cancer Lett2008;269(2):226-42
   PubMed Web of Science ®Google Scholar
• Banerjee S, Zhang Y, Wang Z, et al. In vitro and in vivo molecular evidence of genistein action in augmenting the efficacy of cisplatin in pancreatic cancer. Int J Cancer2007;120(4):906-17
   PubMed Web of Science ®Google Scholar
• Piao M, Mori D, Satoh T, et al. Inhibition of endothelial cell proliferation, in vitro angiogenesis, and the down-regulation of cell adhesion-related genes by genistein. Combined with a cDNA microarray analysis. Endothelium2006;13(4):249-66
   PubMed Web of Science ®Google Scholar
• Kazi A, Daniel KG, Smith DM, et al. Inhibition of the proteasome activity, a novel mechanism associated with the tumor cell apoptosis-inducing ability of genistein. Biochem Pharmacol2003;66(6):965-76
   PubMed Web of Science ®Google Scholar
• Liu Y, Hu M. Absorption and metabolism of flavonoids in the caco-2 cell culture model and a perused rat intestinal model. Drug Metab Dispos2002;30(4):370-7
   PubMed Web of Science ®Google Scholar
• Alvero AB, Kelly M, Rossi P, et al. Anti-tumor activity of phenoxodiol: from bench to clinic. Future Oncol2008;4(4):475-82
   PubMed Web of Science ®Google Scholar
• Alvero AB, O'Malley D, Brown D, et al. Molecular mechanism of phenoxodiol-induces apoptosis in ovarian carcinoma cells. Cancer2006;106(3):599-608
   PubMed Web of Science ®Google Scholar
• Aguero MF, Facchinetti MM, Sheleg Z, Senderowicz AM. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res2005;65(8):3364-73
   PubMed Web of Science ®Google Scholar
• Brown DM, Heaton A, Husband AJ. Idronoxil. Drugs Future2008;33(10):844-60
   Web of Science ®Google Scholar
• Herst PM, Petersen T, Jerram P, et al. The antiproliferative effects of phenoxodiol are associated with inhibition of plasma membrane electron transport in tumour cell lines and primary immune cells. Biochem Pharmacol2007;74(11):1587-95
   PubMed Web of Science ®Google Scholar
• Yagiz K, Morré DJ, Morré DM. Transgenic mouse lineoverexpressing the cancer specific tNOX protein has an enhanced growth and acquired drug-reponse phenotype. J Nutr Biochem2006;17(11):750-9
   PubMed Web of Science ®Google Scholar
• Ziying J, Gorentstin NM, Morré DJ. Molecular cloning and characterization of a candidate human growth-related and time-keeping constitutive cell surface hydroquinone (NADH) oxidase. Biochemistry2008;47(52):14028-38
   PubMed Web of Science ®Google Scholar
• Chueh PJ, Kim C, Cho N, et al. Molecular cloning and characterization of a tumor-associated, growth-related, and time-keeping hydroquinone (NADH) oxidase (tNOX) of the HeLa cell surface. Biochemistry2002;41(11):3732-41
   PubMed Web of Science ®Google Scholar
• Cho N, Morré DJ. Early developmental expression of a normally tumor-associated and drug-inhibited cell surface-located NADH oxidase (ENOX2) in non-cancer cells. Cancer Immunol Immunother2009;58(4):547-52
   PubMed Web of Science ®Google Scholar
• DeLuca T, Morré DM, Zhao H, Morré DJ. NAD-/NADH and/or CoQ/CoQH2 from plasma membrand electron transport may determine ceramide and sphingosine-1-phosphate levels accompanying G1 arrest and apoptosis. Biofactors2005;25(1-4):43-60
   PubMed Web of Science ®Google Scholar
• Kluger HM, Mccarthy MM, Alvero AB, et al. The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization. J Transl Med2007;5:6-20
   PubMed Web of Science ®Google Scholar
• Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res2000;60(19):5451-5
   PubMed Web of Science ®Google Scholar
• Joshua AM, Ong S, Noney L, et al. Phase 1 dose-escalation of phenoxodiol in patients with advanced cancer [abstract 902]. Proc Am Soc Clin Oncol2003;22
   Google Scholar
• Choueiri TK, Mekhail T, Hutson TE, et al. Phase I trial of phenoxodiol delivered by continuous intravenous infusion in patients with solid cancer. Ann Oncol2006;17(5):860-5
   PubMed Web of Science ®Google Scholar
• Available from: http://www.clinicaltrials.gov/ct2/show/NCT00382811? term=ovature&rank=1 [Last assessed 2 Nov 2008]
   Google Scholar
• Wang X, Kim KH, Alvero AB, et al. The mechanism of action of Triphendiol (NV-196) as a monotherapy and a chemosnsitizer against pancreatic cancer. (submitted J Translat Medicine, Feb 2009)
   Google Scholar
• Alvero AB, Montagna MK, Chen R, et al. NV-128, a novel isoflavone derivative, induces caspase-independent cell death through Akt/mTOR pathway. Cancer2009 (In Press)
   PubMedGoogle Scholar
• Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul1984;22:27-55
   PubMedGoogle Scholar
• Wang X, Kim K, Alvero A, et al. Triphendiol (NV-196) induces apoptosis and sensitizes pancreatic cancer cells to gemcitabine [abstract # LB-52]. 99th AACR Annual Meeting–Apr 12-16, 2008; San Diego, CA
   Google Scholar
• Pan G, Vickers SM, Pickens A, et al. Apoptosis and tumorigenesis in human cholangiocarcinoma cells. Involvement of Fas/APO-1 (CD95) and calmodulin. Am J Pathol1999;155(1):193-203
   PubMed Web of Science ®Google Scholar
• Rödicker F, Pützer BM. p73 is effective in p53-null pancreatic cancer cells resistant to wild-type TP53 gene replacement. Cancer Res2003;63(11):2737-41
   PubMed Web of Science ®Google Scholar
• Mainwaring PN, West L, Husband AJ. Phase 1a safety and pharmacokinetic study of oral NV-196 in patients with solid tumours [abstract 14615]. J Clin Oncol2008;26(15S Pt 1):636s
   Google Scholar
• Ruggeri BA, Huang L, Berger D, et al. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions. Cancer1997;79(4):700-16
   PubMed Web of Science ®Google Scholar
• Saif MW, Kang SP, Ledbetter L, et al. Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation? JOP2007;8(6):799-805
   Google Scholar
• Kim MP, Gallick GE. Gemcitabine resistance in pancreatic cancer: picking the key players. Clin Cancer Res2008;14(5):1284-5
   PubMed Web of Science ®Google Scholar
• Schniewind B, Christgen M, Kurdow R, et al. Resistance of pancreatic cancer to gemcitabine treatment is dependent on mitochondria-mediated apoptosis. Int J Cancer2004;109(2):182-8
   PubMed Web of Science ®Google Scholar
• Sebastiani V, Ricci F, Rubio-Viqueira B, et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res2006;12(8):2492-7
   PubMed Web of Science ®Google Scholar
• Nöthlings U, Murphy SP, Wilkens LR, et al. Flavonols and pancreatic cancer risk: the multiethnic cohort study. Am J Epidemiol2007;166(8):924-31
   PubMed Web of Science ®Google Scholar
• Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol2007;25:1960-6
   PubMed Web of Science ®Google Scholar
• Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol2002;20:3270-5
   PubMed Web of Science ®Google Scholar
• Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol2004;22(18):3776-83
   PubMed Web of Science ®Google Scholar
• Louvet C, Labianca R, Hammel P, et al. GERCOR; GISCAD. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol2005;23(15):3509-16
   PubMed Web of Science ®Google Scholar
• Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol2007;25:2212-7
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, et al. A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC) [abstract 108]. A preliminary analysis of Cancer and Leukemia Group B (CALGB ASCO Gastrointestinal Cancers Symposium; 1 – 4 June 2007, Chicago, IL, USA
   Google Scholar
• Philip PA, Benedetti J, Fenoglio-preiser C, et al. Phase III study of gemcitabine [G] plus cetuximab [C] versus gemcitabine in patients [pts] with locally advanced or metastatic pancreatic adenocarcinoma [PC]: SWOG S0205 study ASCO Annual Meeting Proceedings Part I. J Clin Oncol2007;25(18 Suppl):LBA4509
   Web of Science ®Google Scholar
• Saif MW. Erlotinib: the first biologic in the management of pancreatic cancer. Expert Opin Pharmacother2008;9(9):1595-607
   PubMed Web of Science ®Google Scholar